[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
about
The dopamine metabolite 3-methoxytyramine is a neuromodulatorMAO-inhibitors in Parkinson's DiseaseFour decades of neurodegenerative disease research: how far we have come!Dopamine-independent locomotor actions of amphetamines in a novel acute mouse model of Parkinson disease.Neuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesLevodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected FindingThe Human Experience with Intravenous LevodopaDrug-induced dyskinesia in Parkinson's disease. Should success in clinical management be a function of improvement of motor repertoire rather than amplitude of dyskinesia?Parkinson's disease and levodopa. A five-year follow-up and reviewParkinsonism occurring during methyldopa therapyVesicular integrity in Parkinson's diseaseDiagnosis of Parkinson's disease based on disease-specific autoantibody profiles in human seraDopaminergic Neurons Exhibit an Age-Dependent Decline in Electrophysiological Parameters in the MitoPark Mouse Model of Parkinson's Disease.Effect of L-dopa on speech in Parkinsonism. An EMG study of labial articulatory functionDisruption of aminergic signalling reveals novel compounds with distinct inhibitory effects on mosquito reproduction, locomotor function and survival.Development of new levodopa treatment strategies in Parkinson's disease-from bedside to bench to bedsideRole of the ubiquitin proteasome system in Parkinson's disease.Cell-based therapies for Parkinson's disease: past, present, and futureNeuroproteomics as a promising tool in Parkinson's disease research.Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease?Why psychosis is frequently associated with Parkinson's disease?Mitochondrial abnormalities in the putamen in Parkinson's disease dyskinesiaActions of certain amines on cerebral cortical neuronesA dose rising study of the safety and effects on serum prolactin of SK&F 101468, a novel dopamine D2-receptor agonist.The absorption and metabolism of a standard oral dose of levodopa in patients with Parkinsonism.Striatal dopamine neurotransmission: regulation of release and uptakeRecent advances in treating Parkinson's disease.Milestones in research on the pathophysiology of Parkinson's diseaseL-DOPA in Parkinson's Disease.One to two year treatment of Parkinson's disease with levodopaFactors predictive of the development of levodopa-induced dyskinesia and Wearing-Off in Parkinson's disease.Presynaptic effects of levodopa and their possible role in dyskinesia.Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease.Saskatchewan movement disorders program.Dopamine: the rewarding years.Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.mTORC2/rictor signaling disrupts dopamine-dependent behaviors via defects in striatal dopamine neurotransmission.Dopamine-dependent corticostriatal synaptic filtering regulates sensorimotor behavior.Treatment of Parkinson's disease with L-dopa: a current appraisal.Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study
P2860
Q21091097-04CEC074-5E1F-4B29-91B5-1AC77D751DF8Q24629770-84BEB6BF-CD52-4EF9-9F71-0B58239A7D18Q24645662-5D27E2CA-4353-42BB-8017-3EB6CECE5E31Q24815335-CC7EF115-8887-45A2-B14D-B021B93883E7Q26747508-AA1A979D-2630-400F-8119-C2DECECB3631Q26752867-BF8ACD4A-CE2C-40C4-876F-5AA391E4BF13Q26771516-C6C47994-D348-4931-B3BC-39A2ED56DEF9Q27021464-29E515C9-4759-4FBF-AF72-F7652B36C4D7Q28363594-BD42D54A-6F2F-4786-B61B-E963711772D6Q28365568-C18C0971-299E-49F9-845C-6B652085F040Q28385737-C579DE0C-84A7-4677-9876-6802BAEFE6A1Q28731824-29D2AA3C-A45C-48EB-B7B5-22C2CF269D76Q30372768-058C9385-80FE-4836-9749-F487EC816740Q30496141-364E595E-66A0-44B4-BC30-095F5C79B2BFQ30582295-5391F5A9-DB9F-4294-8C1B-699FE8C9FE46Q30852749-4B3DF066-A52A-44A0-8884-1FF4E4330B7AQ33307874-5DE626ED-F71D-4B6D-86E6-399FC90B82BEQ33818127-A4DDD17E-99E0-4C07-81BC-6C356201E48DQ33821316-079FEE24-AB54-45D6-B4A1-59D580BBBBB9Q34044620-C9833849-EC94-4E28-A580-FD676CFFCA11Q34094668-2C08A58B-48A1-4A2A-8D10-0648E57751B7Q34203904-D004EFE4-DE21-4689-80F4-B2397150D24AQ34254856-0CEC4771-9D23-40DA-B9B0-5BAAD74C1D44Q34397911-4F8F5B1C-2DC7-49DC-AD73-472EDC7E354FQ34451423-064D8484-9F04-4D29-915F-A81EE31F5158Q34524803-7BC5D913-8A07-4630-B75A-70B020ABD0B3Q34554401-38FB3576-8436-4D3C-922E-69A6966CEE2AQ34749047-00D77A95-64B8-49AC-9DA0-B1B90B8546D1Q34769217-DF1F035E-789C-4216-AB84-713DFCA9B6B8Q34769814-187ABAC0-9F6E-443A-A8E8-CBFEF204374FQ34854202-496966C6-6914-43F8-A136-25CBBC205A5CQ35040280-FBF4938F-5658-497D-B04C-39E1DD2ADDBBQ35072636-ACD20164-84EE-4125-BA7C-71F5867396DFQ35559550-39F042A2-0B13-4EC0-8640-76E89F9B7C45Q35566619-4E9803A1-CE1E-4478-B1E5-928F752C5FB4Q35614156-A3C66AC1-7FDD-423B-9441-CC1952E64C8AQ35707905-265CA7D8-3C1B-4412-8E6F-EFB6980D55CAQ35828317-10EBC311-C0C4-4485-A1AE-E52F9B62892BQ35909824-4B866ED5-34BB-4672-A900-F7A252C6DC6AQ35910081-9F81FABC-4486-4B90-B873-AFECAD84C406
P2860
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
description
1961 nî lūn-bûn
@nan
1961 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1961 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1961年の論文
@ja
1961年論文
@yue
1961年論文
@zh-hant
1961年論文
@zh-hk
1961年論文
@zh-mo
1961年論文
@zh-tw
1961年论文
@wuu
name
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@ast
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@en
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@nl
type
label
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@ast
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@en
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@nl
prefLabel
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@ast
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@en
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@nl
P1476
[The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]
@en
P2093
BIRKMAYER W
HORNYKIEWICZ O
P304
P577
1961-11-01T00:00:00Z